LDAi™ (Lung Density Analysis–Inspiration) provides fully-automated detection, visualization and quantification of areas of low attenuation (LAA) which can be indicative of emphysema. LDAi is validated for use with low-dose CT scans as a component of lung cancer screening programs and includes a patient-centered LungMap™ report to assist with smoking cessation counseling. LDAi provides results based on a standard inspiratory chest CT.
FDA 510(k) Cleared, ARTG Approved, CE Mark Certified, Health Canada Approved
With LDAi, descriptive terminology such as ‘mild’ or ‘moderate’ is no longer acceptable to accurately assess COPD or emphysema.
LDAi is a fully automated solution delivering quantitative analysis and 3D visualization to the patient study in PACS. LDAi includes Noise Reduction Technology (NRT) to aid quantification and visualization of low dose scans, and also includes Patient LungMap™ report to aid smoking cessation counseling.
Imbio, a fully owned subsidiary of 4DMedical, is the legal manufacturer of LDAi
